[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-solid-tumors-harboring-ras-mutations-or-amplifications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-solid-tumors-harboring-ras-mutations-or-amplifications":57},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100607545",false,"NCT07189949","A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","A Phase I Study of HRS-2329 Evaluating Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","Inclusion Criteria:\n\n1. Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;\n2. Aged between 18-75 years old;\n3. Participants with histologically\u002Fcytologically confirmed advanced solid tumors who have been previously tested or are confirmed by the central laboratory to harbor RAS mutations or amplifications and have failed standard treatment;\n4. ECOG performance status (PS) score of 0 or 1;\n5. Life expectancy \\> 3 months;\n6. At least one measurable lesion per RECIST v1.1;\n7. Adequate organ function.\n\nExclusion Criteria:\n\n1. Toxicity (e.g., gastrointestinal reaction and skin toxicity) from prior anti-tumor treatment has not recovered to Grade ≤ 1 or a level specified in the inclusion\u002Fexclusion criteria;\n2. Presence of central nervous system (CNS) metastases;\n3. Participants with gastrointestinal diseases that affect drug administration\u002Fabsorption;\n4. Participants who have undergone major surgery other than diagnosis or biopsy within 28 days before the first dose, or are expected to undergo major surgery during the study period;\n5. Presence of serious pulmonary diseases;\n6. Active tuberculosis or a history of active tuberculosis infection within 48 weeks prior to screening, regardless of whether they have been treated;\n7. Active or persistent gastrointestinal bleeding within 6 months prior to screening;\n8. History of allogeneic bone marrow or solid organ transplantation;\n9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;\n10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;\n11. Positive human immunodeficiency virus (HIV) (HIV1\u002F2 antibodies), active chronic hepatitis B, or active hepatitis C (positive HCV antibody and positive HCV RNA);\n12. Known history of hypersensitivity to any component of the drug product to be used in the study.","ALL","18 Years","75 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.",[26],"Advanced Solid Tumors Harboring RAS Mutations or Amplifications","RECRUITING","2026-03-05",{"date":30,"type":31},"2026-03-06","ACTUAL",{"date":33,"type":31},"2025-10-16",{"date":35,"type":20},"2028-12",{"name":37,"class":38},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":47,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":39},"100603935","NCT07142980","A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","A Phase I Study of HRS-7172 Evaluating Safety, Tolerability and Pharmacokinetics in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","Inclusion Criteria:\n\n1. Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;\n2. Aged between 18-75 years old;\n3. ECOG performance status (PS) score of 0 or 1;\n4. Life expectancy \\> 3 months;\n5. At least one measurable lesion per RECIST v1.1;\n6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Toxicity from prior anti-tumor treatment has not recovered to Grade ≤ 1 or a level specified in the inclusion\u002Fexclusion criteria;\n2. Presence of central nervous system (CNS) metastases;\n3. Participants with gastrointestinal diseases that affect drug administration\u002Fabsorption;\n4. Participants who have undergone major surgery other than diagnosis or biopsy within 28 days before the first dose, or are expected to undergo major surgery during the study period;\n5. Presence of serious pulmonary diseases;\n6. Active tuberculosis or a history of active tuberculosis infection within 48 weeks prior to screening, regardless of whether they have been treated;\n7. Active or persistent gastrointestinal bleeding within 6 months prior to screening;\n8. History of allogeneic bone marrow or solid organ transplantation;\n9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;\n10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;\n11. Positive human immunodeficiency virus (HIV) (HIV1\u002F2 antibodies), active chronic hepatitis B, or active hepatitis C (positive HCV antibody and positive HCV RNA);\n12. Known history of hypersensitivity to any component of the drug product to be used in the study.",{"count":19,"type":20},[23],"This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.",[26],"2025-11-13",{"date":52,"type":31},"2025-11-17",{"date":54,"type":31},"2025-09-12",{"date":35,"type":20},{"name":37,"class":38},""]